| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Mohammad Hassan A Noureldine | Q57525866 |
| Ali Haydar | Q85822381 | ||
| P2093 | author name string | G R V Hughes | |
| I Uthman | |||
| A Berjawi | |||
| M Merashli | |||
| M Skaf | |||
| P2860 | cites work | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis | Q22252943 |
| Thrombosis, abortion, cerebral disease, and the lupus anticoagulant | Q24675412 | ||
| Multiple sclerosis: side effects of interferon beta therapy and their management | Q28137954 | ||
| Autoimmune optic neuropathy with anticardiolipin antibody mimicking multiple sclerosis in a child | Q28196877 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Multiple sclerosis | Q29616022 | ||
| MRI in the diagnosis and management of multiple sclerosis | Q30689332 | ||
| Immunoserological changes in the cerebro-spinal fluid and serum in systemic lupus erythematosus patients with demyelinating syndrome and multiple sclerosis | Q30834779 | ||
| MRI and the brain in systemic lupus erythematosus | Q30887269 | ||
| APS and the brain | Q33196667 | ||
| Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study | Q33303065 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop | Q33685960 | ||
| Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature | Q33835528 | ||
| Epidemiology of the antiphospholipid antibody syndrome | Q33916234 | ||
| The diagnosis of multiple sclerosis | Q34131537 | ||
| New diagnostic criteria for multiple sclerosis: guidelines for research protocols | Q34271601 | ||
| Environmental risk factors in multiple sclerosis aetiology | Q34369999 | ||
| Immune-mediated side-effects of cytokines in humans | Q34380747 | ||
| Interferons in relapsing remitting multiple sclerosis: a systematic review | Q34531565 | ||
| Central nervous system involvement in the antiphospholipid (Hughes) syndrome | Q35069507 | ||
| Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes') syndrome | Q35075610 | ||
| Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies | Q35189295 | ||
| Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study | Q35455167 | ||
| Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. | Q35467118 | ||
| Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis | Q35636977 | ||
| The interface of multiple sclerosis and antiphospholipid antibodies | Q35928731 | ||
| Antiphospholipid (Hughes) syndrome | Q35934717 | ||
| Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? | Q36006209 | ||
| Psychiatric side effects of interferon-beta in multiple sclerosis | Q36357179 | ||
| Etiology of Balkan endemic nephropathy and associated urothelial cancer | Q36359803 | ||
| Multiple sclerosis--the plaque and its pathogenesis | Q36410882 | ||
| The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration | Q36610350 | ||
| Autoantibodies and neurodegeneration in multiple sclerosis | Q37180839 | ||
| Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study | Q39554013 | ||
| Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells | Q40997117 | ||
| Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients | Q48162703 | ||
| A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? | Q48373517 | ||
| Gadolinium-enhanced magnetic resonance imaging of the central nervous system in systemic lupus erythematosus | Q48423132 | ||
| MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis | Q48504500 | ||
| Hypoperfusion of brain single photon emission computerized tomography in patients with antiphospholipid antibodies | Q48805163 | ||
| [Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients]. | Q50860211 | ||
| Frequency and significance of antinuclear antibodies in multiple sclerosis. | Q50933376 | ||
| PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS | Q57075856 | ||
| Multiple sclerosis in Latin America | Q57217519 | ||
| Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis | Q57602063 | ||
| Prevalence and Clinical Significance of Anti-phospholipid Antibodies in Multiple Sclerosis: a Study of 89 Patients | Q58854442 | ||
| P433 | issue | 2 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 115-121 | |
| P577 | publication date | 2014-10-17 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Hughes syndrome and multiple sclerosis | |
| P478 | volume | 24 |
| Q64074958 | Antiphospholipid Antibodies Overlapping in Isolated Neurological Syndrome and Multiple Sclerosis: Neurobiological Insights and Diagnostic Challenges |
| Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
| Q38841201 | Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria? |
| Q33423959 | Current treatment of antiphospholipid syndrome: lights and shadows |
| Q31101744 | Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies? |
| Q33705977 | Internal Carotid Artery Occlusion in Systemic Lupus Erythematosus as a Potential Mimicker of Multiple Sclerosis. |
| Q38753531 | Musculoskeletal manifestations of the antiphospholipid syndrome |
| Q27027588 | Neuropsychiatric lupus: a mosaic of clinical presentations |
Search more.